| Document |
Document Title |
|
WO/2005/077895A1 |
The invention provides cytokine production inhibitors useful as preventive or therapeutic agents for diseases accompanied with abnormally enhanced immune function. Cytokine production inhibitors containing as the active ingredient thioam...
|
|
WO/2005/077915A1 |
The present invention relates to certain novel compounds of Formula (I): Formula (I) methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of integrin mediated disorders.
|
|
WO/2005/075437A1 |
Compounds of formula (1) are effective PDE4 inhibitors in which R1 is 1-4C-alkyl and R2 is 1-4C-alkyl, R3 represents a phenyl dervative of formulae (a) or (b) wherein R4 is 1-4C-alkoxy or 1-4C-alkoxy which is completely or predominantly ...
|
|
WO/2005/074938A1 |
A drug for inhibiting vascular intimal hyperplasia which is effective in the prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) and stent placement in a blood vessel or effective in treatments for the pr...
|
|
WO/2005/075438A1 |
The present invention relates to novel compounds of formula (I), processes for their preparation, compositions comprising them and their use in the treatment or prevention of diseases capable of being modulated by the inhibition of cell ...
|
|
WO/2005/070891A2 |
Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutically compo...
|
|
WO/2005/068445A2 |
The invention relates to compounds of formula (I) wherein Het, A1, A2, A3, A4, D, W, T, Q, Y, X1, X2, R1, R2, R3, R4, k and m are as defined hereinabove, and, where applicable, to possible E/Z isomers, mixtures of E/Z isomers and/or taut...
|
|
WO/2005/066138A1 |
Disclosed are amides of formula (I), wherein the symbols have the meanings indicated in the description, a method for producing said substances, the use thereof for controlling undesired microorganisms, as well as intermediate products o...
|
|
WO/2005/058884A2 |
The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane c...
|
|
WO/2005/058845A2 |
Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists. (I) wherein A is (II), (III) or (IV), Y is a valence b...
|
|
WO/2005/055715A2 |
Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, Ra, Rb, Rc, Rd, b, c, Re, Rf, Rg, Rh, R5, d, e, U...
|
|
WO/2005/054199A1 |
Compounds of general formula (I), (II) (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associa...
|
|
WO/2005/051302A2 |
Disclosed are compounds of the Formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R8, R9 and R10, W, X, and Z are as defined in the specification. Such compounds are MEK inhibitors and useful in the t...
|
|
WO/2005/051870A2 |
The present invention describes a process to form hydrazides from the reaction of a hydrazine and a dicarboxylic, using a Lewis acid as a main reagent of the reaction. The reaction occurs in a safe reactional environment, utilizing smoot...
|
|
WO/2005/051906A2 |
Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X, Y and Z are as defined in the specification. Such compounds are MEK inhibitors and are useful in th...
|
|
WO/2005/051301A2 |
Disclosed are compounds of the Formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the tre...
|
|
WO/2005/051300A2 |
Disclosed are compounds of the Formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, R10, R20, R21, and R22 are as defined in the specification. Such compounds are MFK inhibitors and useful i...
|
|
WO/2005/049581A1 |
New pyridazin-e-(2H)-one derivatives having the chemical structure of general formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of ph...
|
|
WO/2005/049573A1 |
This invention relates to compounds of Formula (I) wherein one of R5, R6 and R7 is (Formula II), and X1, X2, Y1 to Y4, R1 to R13 and m and n are as defined in the description, and to all enantiomers and pharmaceutically acceptable salts ...
|
|
WO/2005/037844A1 |
The inVention is related to new substituted phenyl fused heterocycle compounds having herbicidal activities, these compounds are characterized by high efficiency, low toxicity, high selectivity, and the like.
|
|
WO/2005/037793A1 |
Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, B, Z, R1, R2a, R2b, R8, R9, and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions...
|
|
WO/2005/035518A1 |
The invention relates to compounds of formula (I), to a method for the production thereof, and to their use as antiphlogistics.
|
|
WO/2005/035514A2 |
The present invention provides compounds of Formula (I) useful as modulators of ABC transporter activity, or a pharmaceutically acceptable salt thereof, wherein RB, n, B, RC, RD, RE, A, and Z are described generally and in classes and su...
|
|
WO/2005/035500A2 |
The invention provides a compound of formula (I) (where R1, R1’, R2, R3, X, Y, Z and n are disclosed herein) or a pharmaceutically acceptable salt thereof (s “Diaminoalkylene Compound”); pharmaceutical compositions comprising an ef...
|
|
WO/2005/034939A1 |
The invention relates to polysubstituted tetrahydronaphtalene derivatives of formula (I), to methods for the production thereof, and to their use as antiphlogistics. The substituents are defined in Claim 1.
|
|
WO/2005/033105A2 |
Compounds having the general structure formula (I) and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascula...
|
|
WO/2005/030830A1 |
A compound (monomer) comprising i) one or more dienophile groups (A-functional groups), ii) one or more ring structures comprising two conjugated carbon-to-carbon double bonds and a leaving group L (B-functional groups), and iii) one or ...
|
|
WO/2005/030213A1 |
Compounds of Formula (IA), IB), IC), and (ID) wherein R1, R2, R3, R4, R5, and R6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions con...
|
|
WO/2005/028449A1 |
The invention relates to an improved process for the manufacture of 1,2-disubstituted hexahydro-pyridazine-3-carboxylic acids and esters thereof by reacting N,N’-disubstituted hydrazine with 2,5-dihalogenated valeric acids and thereof ...
|
|
WO/2005/023260A1 |
A compound of formula (I) wherein the substituents are described in claim 1 for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive process...
|
|
WO2005003098B1 |
The invention relates to pentanol derivatives of general formula (I), which are substituted by quinazoline, quinoxaline, cinnoline, indazole, phthalazine, naphthyridine, benzothiazole, dihydroindolone, dihydroisoindolone, benzimidazole, ...
|
|
WO/2005/016264A2 |
Diamine derivatives of quinones, and related compounds, including salts thereof, that modulate the levels of gene expression in cellular systems, such as cancer cells, are disclosed, along with methods for preparing such compounds and de...
|
|
WO/2005/016890A1 |
Compounds of Formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
|
|
WO/2005/013995A1 |
Compounds of formula (I) wherein Z, A, R, R1, R2, R3 have the meanings defined in the specification, the N-oxidized derivatives of the compounds of formula (I), the pharmaceutically acceptable salts thereof, pharmaceutical compositions c...
|
|
WO/2005/013914A2 |
The present invention relates to compounds such as those of formula (I-A) inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and met...
|
|
WO/2005/013907A2 |
Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modul...
|
|
WO/2005/011657A2 |
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where G, J, L, M, x, y, W, V, R2, ...
|
|
WO/2005/011653A2 |
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R2, R3, R4, R5, ...
|
|
WO/2005/012259A1 |
A method of inhibiting OPN production, characterized by administering an effective amount of either a pyridazine derivative represented by the general formula (I): (Chemical formula 10) (I) (wherein R1 represents optionally substituted p...
|
|
WO/2005/011655A2 |
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I), where x, y, W, V, R2, R3, R4, R5, ...
|
|
WO/2005/009971A1 |
A platelet aggregation inhibitor which contains a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient; and a novel quinolone derivative or a pharmaceutically acceptable salt thereof which are useful...
|
|
WO/2005/009976A1 |
The present invention relates to piperazines of formula I. The compounds show a high and selective binding affinity for the histamine H3 receptor, indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As...
|
|
WO/2005/007632A1 |
Disclosed are substituted pyridazinones that are useful for treating diseases and conditions caused or 5 exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical composition containing the pyridazinone compounds, met...
|
|
WO/2004/108690A1 |
The invention provides pyrimidine, pyridazine and triazine compounds for use in therapy.
|
|
WO/2004/099146A1 |
The present invention provides benzamide inhibitors of the P2X7 receptor of the formula (I), wherein R1 -R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without ...
|
|
WO/2004/099158A1 |
Compounds and compositions containing compounds given by the structural Formula 8, for tumor therapeutic applications are disclosed. A and B are each independently selected from C is selected from D is selected from -N-, -NO-, NR10, -CR1...
|
|
WO/2004/089412A1 |
An inhibitor for the hyperfunction of NAD(P)H oxidase containing a compound which substantially does not inhibit NADPH oxidase originating in leukocytes but inhibits NAD(P)H oxidase originating in tissues other than leukocytes, and a med...
|
|
WO/2004/084842A2 |
The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., ca...
|
|
WO/2004/085406A1 |
This invention relates to novel pyridazinone derivatives of formula (I) wherein R1-R4, R7, R8 and X1 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodef...
|
|
WO/2004/083188A1 |
A phenylpyridazine derivative represented by the general formula (1): (1) (wherein R1, R2, R3, X, Y, Z, and n are the same as defined in the description) or a salt thereof; and a medicine containing the derivative or salt. The phenylpyri...
|
